Abstract
Over the past 40 years, big efforts have been devoted to the development of novel folate antimetabolites. All of the potent antifolates have reportedly been inhibitors of dihydrofolate reductase (DHFR). In 1985, Taylor and et al. reported the synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid, DDATHF, which exhibits broad and selective antitumor activity as an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT). DDATHF is a close analog of tetrahydrofolic acid, differs only by replacement of the 5- and 10- position nitrogen atoms by carbon. It may exist in two diastereomeric forms, differing in configuration at carbon 6. Both diastereomers of DDATHF are potent inhibitors of cell growth in culture. DDATHF is currently in Phase II clinical trials
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.